tetano
Editor, Senior Moderator
Clin Immunol
. 2021 Aug 31;231:108845.
doi: 10.1016/j.clim.2021.108845. Online ahead of print.
Impact of the COVID-19 pandemic in patients with systemic lupus erythematosus throughout one year
Giuseppe A Ramirez[SUP] 1 [/SUP], Lorenza M Argolini[SUP] 2 [/SUP], Chiara Bellocchi[SUP] 3 [/SUP], Luca Moroni[SUP] 4 [/SUP], Emanuel Della-Torre[SUP] 4 [/SUP], Nicola Farina[SUP] 4 [/SUP], Roberto F Caporali[SUP] 5 [/SUP], Lorenzo Beretta[SUP] 3 [/SUP], Maria Gerosa[SUP] 5 [/SUP], Enrica P Bozzolo[SUP] 6 [/SUP], Lorenzo Dagna[SUP] 4 [/SUP], SMILE, Milan Lupus Consortium
Affiliations
Abstract
Little is known about the impact of coronavirus disease 2019 (COVID-19) pandemic to the care of patients with systemic lupus erythematosus (SLE) in the long-term. By crossing population data with the results of a web-based survey focused on the timeframes January-April and May-December 2020, we found that among 334/518 responders, 28 had COVID-19 in 2020. Seventeen cases occurred in May-December, in parallel with trends in the general population and loosening of containment policy strength. Age > 40 years (p = 0.026), prednisone escalation (p = 0.008) and infected relatives (p < 0.001) were most significantly associated with COVID-19. Weaker associations were found with asthma, lymphadenopathy and azathioprine or cyclosporine treatment. Only 31% of patients with infected relatives developed COVID-19. Healthcare service disruptions were not associated with rising hospitalisations. Vaccination prospects were generally welcomed. Our data suggest that COVID-19 has a moderate impact on patients with SLE, which might be significantly modulated by public health policies, including vaccination.
Keywords: COVID-19; Containment; Coronavirus; Lockdown; Prednisone; Public health; Systemic lupus erythematosus; Treatment; Vaccination.
. 2021 Aug 31;231:108845.
doi: 10.1016/j.clim.2021.108845. Online ahead of print.
Impact of the COVID-19 pandemic in patients with systemic lupus erythematosus throughout one year
Giuseppe A Ramirez[SUP] 1 [/SUP], Lorenza M Argolini[SUP] 2 [/SUP], Chiara Bellocchi[SUP] 3 [/SUP], Luca Moroni[SUP] 4 [/SUP], Emanuel Della-Torre[SUP] 4 [/SUP], Nicola Farina[SUP] 4 [/SUP], Roberto F Caporali[SUP] 5 [/SUP], Lorenzo Beretta[SUP] 3 [/SUP], Maria Gerosa[SUP] 5 [/SUP], Enrica P Bozzolo[SUP] 6 [/SUP], Lorenzo Dagna[SUP] 4 [/SUP], SMILE, Milan Lupus Consortium
Affiliations
- PMID: 34478882
- PMCID: PMC8405598
- DOI: 10.1016/j.clim.2021.108845
Abstract
Little is known about the impact of coronavirus disease 2019 (COVID-19) pandemic to the care of patients with systemic lupus erythematosus (SLE) in the long-term. By crossing population data with the results of a web-based survey focused on the timeframes January-April and May-December 2020, we found that among 334/518 responders, 28 had COVID-19 in 2020. Seventeen cases occurred in May-December, in parallel with trends in the general population and loosening of containment policy strength. Age > 40 years (p = 0.026), prednisone escalation (p = 0.008) and infected relatives (p < 0.001) were most significantly associated with COVID-19. Weaker associations were found with asthma, lymphadenopathy and azathioprine or cyclosporine treatment. Only 31% of patients with infected relatives developed COVID-19. Healthcare service disruptions were not associated with rising hospitalisations. Vaccination prospects were generally welcomed. Our data suggest that COVID-19 has a moderate impact on patients with SLE, which might be significantly modulated by public health policies, including vaccination.
Keywords: COVID-19; Containment; Coronavirus; Lockdown; Prednisone; Public health; Systemic lupus erythematosus; Treatment; Vaccination.